- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3259EUR$3,750USD£2,841GBP
- Report
- July 2024
- 150 Pages
Global
From €3259EUR$3,750USD£2,841GBP
- Report
- July 2024
- 150 Pages
Global
From €3259EUR$3,750USD£2,841GBP
- Report
- July 2024
- 100 Pages
Global
From €3259EUR$3,750USD£2,841GBP
- Report
- June 2024
- 200 Pages
Global
From €6908EUR$7,950USD£6,022GBP
- Report
- January 2024
- 189 Pages
Global
From €6517EUR$7,500USD£5,681GBP
- Report
- November 2023
- 30 Pages
Global
From €2390EUR$2,750USD£2,083GBP
- Report
- November 2023
- 30 Pages
Global
From €2390EUR$2,750USD£2,083GBP
- Report
- November 2023
- 30 Pages
Global
From €2390EUR$2,750USD£2,083GBP
- Report
- February 2023
- 107 Pages
Global
From €6517EUR$7,500USD£5,681GBP
- Report
- February 2023
- 50 Pages
Global
From €3432EUR$3,950USD£2,992GBP
From €3041EUR$3,500USD£2,651GBP
- Report
- February 2025
- 85 Pages
India
From €3041EUR$3,500USD£2,651GBP
- Report
- December 2024
- 85 Pages
India
From €3041EUR$3,500USD£2,651GBP
- Report
- August 2024
- 150 Pages
Global
From €3259EUR$3,750USD£2,841GBP
- Report
- February 2024
- 30 Pages
Global
From €2824EUR$3,250USD£2,462GBP
- Report
- April 2025
- 85 Pages
Saudi Arabia
From €3041EUR$3,500USD£2,651GBP
- Report
- January 2025
- 133 Pages
Europe
From €3476EUR$4,000USD£3,030GBP
- Report
- December 2024
- 85 Pages
Spain
From €3041EUR$3,500USD£2,651GBP
- Report
- August 2024
- 80 Pages
Japan
From €3041EUR$3,500USD£2,651GBP

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more